CompletedEUCTR 2017-000736-33
A randomized, subject and investigator blinded, placebo-controlled, parallel group study to investigate whether AFQ056 reduces cocaine use in patients diagnosed with Addiction (CUD).
This historical record does not confirm current site availability.
Historical research recordSpain
Understand this study
What did researchers investigate?
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
- Listed locations
- Spain
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateNot clearly listed
- Recruitment status
- Completed
- Enrollment listed in the registry
- 60
- Sponsor
- Novartis Farmacéutica S.A.
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- Spain
- Age range
- Not clearly listed
- Official registry ID
- EUCTR 2017-000736-33
- Official title
Show the full official title
A randomized, subject and investigator blinded, placebo-controlled, parallel group study to investigate whether AFQ056 reduces cocaine use in patients diagnosed with Cocaine Use Disorder (CUD).
Recruitment & locations
CompletedSpain
Registry details
Historical country statuses
- Spain — Completed
Questions about this study
Who is behind this study?
The study sponsor is Novartis Farmacéutica S.A.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meRelated studies
A PHASE 4, NON-TREATMENT FOLLOW-UP FOR CARDIAC ASSESSMENTS FOLLOWING USE OF SMOKING CESSATION TREATMENTS IN SUBJECTS WITH AND WITHOUT A HISTORY OF PSYCHIATRIC DISORDERS
A PHASE 4, RANDOMIZED, DOUBLE-BLIND, ACTIVE AND PLACEBO -CONTROLLED, MULTICENTER STUDY EVALUATING THE NEUROPSYCHIATRIC SAFETY AND EFFICACY OF 12 WEEKS VARENICLINE TARTRATE 1MG BID AND BUPROPION HYD...